TG-1801

TG-1801

A Phase 1 First-in-Human Study of Bispecific Antibody TG-1801 in Subjects With B-Cell Lymphoma

Disease:

B-Cell Lymphoma

Summary:

Patients with relapsed or refractory B-Cell Lymphoma will receive weekly infusions of TG-1801 for the first 2 cycles (2 months) and then monthly infusions, for a total of 6 months maximum treatment

Eligibility:

Include, but not limited to, the following:

Inclusion criteria:
1. Patients must be 18 years or over
2. Relapsed or refractory B-Cell Lymphoma
3. Measurable disease and adequate organ function (as specified in the protocol)
4. No other active cancers
5. No other major health problems

Exclusion Criteria:
1. Subjects receiving cancer therapy or investigational drug within 21 days of Cycle 1 Day
2. Prior autologous stem cell transplant within 6 months
3. Active Hepatitis B or Hepatitis C

Contact person:

Lewis Edwards
Email cancertrialshaem1@linear.org.au
Phone 08 9386 5125


Email
Phone

Principal Investigator:

A/Prof Chan Cheah

08 6457 7600

Sponsor:

TG Therapeutics, Inc

Phase:

1

Protocol Number:

TG-1801-101

Trial Registration Number:

NCT03804996

Clinical Trials.gov

ANZ Clinical Trial Registry